You are here

ICER

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

Endpoints

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Flag link:

ICER seeks to make drug price research more accessible

ICER seeks to make drug price research more accessible

Biopharma Dive

Flag link:

ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’

ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’

Endpoints

antidepressants

Flag link:

ICER's Growing Impact On Drug Pricing And Reimbursement

ICER's Growing Impact On Drug Pricing And Reimbursement

Forbes

Flag link:

Should Biogen Investors Be Extra Nervous Right Now?

Should Biogen Investors Be Extra Nervous Right Now?

Motley Fool

Alzheimer's disease

Flag link:

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER

Fierce Pharma

spinal muscular atrophy

Flag link:

Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate

Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate

Xconomy

Flag link:

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy

BioCentury

spinal muscular atrophy

Flag link:

The list of shame no biopharma wants to join

The list of shame no biopharma wants to join

EP Vantage

Flag link:

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies

Fierce Pharma

spinal muscular atrophy

alternative payments

Flag link:

Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes

Cost watchdog ICER lays out plans to scrutinize pharma's costliest price hikes

Fierce Pharma

Flag link:

ICER to probe for clinical justification of drug price hikes

ICER to probe for clinical justification of drug price hikes

BioCentury

Flag link:

ICER says gene therapy may be more cost effective for spinal muscular atrophy

ICER says gene therapy may be more cost effective for spinal muscular atrophy

Yahoo/Reuters

spinal muscular atrophy

Flag link:

ICER weighing issuing advice on trial design

ICER weighing issuing advice on trial design

BioCentury

clinical trials

Flag link:

Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says

Prior authorization limits would be 'reasonable' for CGRP drugs, ICER says

Biopharma Dive

coverage limits

Flag link:

Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail

Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail

Fierce Pharma

Flag link:

AbbVie's elagolix could put pressure on budgets, ICER estimates

AbbVie's elagolix could put pressure on budgets, ICER estimates

Biopharma Dive

Flag link:

Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing

Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing

Fierce Pharma

breakthrough status

Flag link:

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

BioWorld

Gilead Sciences

Flag link:

Vantage view – Payers OK with CAR-T? Not so fast

Vantage view – Payers OK with CAR-T? Not so fast

EP Vantage

Flag link:

Pages